Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gsk Plc ADR (NY: GSK )

33.96 +0.26 (+0.77%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
Looking into the current session, GlaxoSmithKline Inc. (NYSE:GSK) is trading at $39.92, after a 0.80% drop. Over the past month, the stock decreased by 0.78%, but over the... 
Via Benzinga
Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage... 
Via Benzinga
Exposures COVID-19
COVID-19 Vaccine-Induced Blood Clots Probably Linked To Amino Acids, Study Shows: WSJ
Researchers have pointed a handful of amino acids targeted by key antibodies of some people who received the AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
Nvidia Launches Supercomputer To Help Advance Fields Of Digital Biology, Genomics
Chip supplier Nvidia Corp (NASDAQ: NVDA) on Tuesday launched Cambridge-1, which it claims is the fastest supercomputer in the United Kingdom, dedicated to the healthcare industry... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Why Alector Zoomed 12% Higher Today
The company has yet another fine July trading day thanks to a Citigroup analyst. 
Via The Motley Fool
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
People Needed
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
Exposures Labor
Why Alector Blasted Higher Today
It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant. 
Via The Motley Fool
Arrowhead Stock Plunges, Alector Stock Surges On Drug News
Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
Via Investor's Business Daily
GlaxoSmithKline's Board Backs CEO Walmsley After Elliott's Letter For Management Shakeup
GlaxoSmithKline plc (NYSE: GSK) said its board sees Chief Executive Emma Walmsley as the right person to lead its pharmaceutical business after the upcoming split... 
Via Benzinga
ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher
Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). 
Via InvestorPlace
Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK
Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two... 
Via Benzinga
Is a Bigger Shake-Up at GlaxoSmithKline on the Way?
An activist investor seems to be pushing for one. 
Via The Motley Fool
New Month And Half Year
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
Activist Fund Elliott Management Wants GlaxoSmithKline Board Shakeup For 'Years Of Under Management'
Elliott Management has finally made its intentions around GlaxoSmithKline plc (NYSE: GSK) known and calls for changes to rescue GSK from what it called "years... 
Via Benzinga
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
The sample size was small, but the results were impressive. 
Via The Motley Fool
Exposures COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
AstraZeneca COVID-19 Vaccine Shows Higher Immune Response With Longer Gap, Third Booster Dose
A sub-analysis from the Oxford-led COV001 and COV002 trials with AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine induced strong immune responses following... 
Via Benzinga
Exposures COVID-19
Wednesday Is A Normal Day
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
A Look Into GlaxoSmithKline's Debt
Over the past three months, shares of GlaxoSmithKline (NYSE:GSK) increased by 9.84%. Before we understand the importance of debt, let us look at how much debt... 
Via Benzinga
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme... 
Via Benzinga
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott Management
GlaxoSmithKline Plc's (NYSE: GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical change at the company... 
Via Benzinga
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.